Immunoprevention Strategies for Colorectal Cancer in Lynch Syndrome Carriers.

Abstract: The immune revolution that swept the field of oncology in the mid-2010s with the advent of checkpoint inhibitors has led to a paradigm shift in approaches toward adapting new cancer prevention modalities. Cancer vaccines have emerged from this era with astounding potential as a durable intervention to prevent cancers especially for patients with hereditary susceptibilities such as Lynch syndrome carriers. This review covers new insights in the immunoprevention landscape for patients living with Lynch syndrome including highlights ranging from clinical trials exploring the use of chemoprevention agents to boost immune cellularity to investigative studies using novel vaccine approaches to induce long-term antitumor immunity.
Competing Interests: Conflicts of Interest and Source of Funding: E.V. had a consulting or advisory role with Janssen Research and Development, Recursion Pharma, Guardant Health, Rising Tide Foundation, and Nouscom, s.r.l. He has received research support from Janssen Research and Development. This work was supported by grants CA260761 and CA257375 (US National Institutes of Health/National Cancer Institute) to E.V. For the remaining authors none were declared.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)